CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$40.19+0.04 (+0.10%)
Close on Nov 18, 2026Market cap $3.89BP/E –Yield –
CRISPR Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
CRISPR Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $13.39M, down 64.8% year over year. For fiscal 2025 it was $3.51M, down 90.6% from the year before. Over ten years it grew 30.4% a year on average. The highest annual figure on record is $914.96M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.51M | -90.6% |
| FY2024 | Dec 31, 2024 | $37.31M | -89.9% |
| FY2023 | Dec 31, 2023 | $371.21M | +30885.5% |
| FY2022 | Dec 31, 2022 | $1.20M | -99.9% |
| FY2021 | Dec 31, 2021 | $914.96M | +127154.9% |
| FY2020 | Dec 31, 2020 | $719.00K | -99.8% |
| FY2019 | Dec 31, 2019 | $289.59M | +9169.8% |
| FY2018 | Dec 31, 2018 | $3.12M | -92.4% |
| FY2017 | Dec 31, 2017 | $41.00M | +693.9% |
| FY2016 | Dec 31, 2016 | $5.16M | +1990.7% |
| FY2015 | Dec 31, 2015 | $247.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $10.18M | +1041.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.46M | +68.6% |
| Q4 FY2025 | Dec 31, 2025 | $864.00K | -97.6% |
| Q3 FY2025 | Sep 30, 2025 | $889.00K | +47.7% |
| Q2 FY2025 | Jun 30, 2025 | $892.00K | +72.5% |
| Q1 FY2025 | Mar 31, 2025 | $865.00K | +71.6% |
| Q4 FY2024 | Dec 31, 2024 | $35.69M | -82.3% |
| Q3 FY2024 | Sep 30, 2024 | $602.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $517.00K | -99.3% |
| Q1 FY2024 | Mar 31, 2024 | $504.00K | -99.5% |
| Q4 FY2023 | Dec 31, 2023 | $201.21M | +3353333.3% |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $70.00M | +44203.8% |
| Q1 FY2023 | Mar 31, 2023 | $100.00M | +10538.3% |
| Q4 FY2022 | Dec 31, 2022 | $6.00K | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $94.00K | -88.6% |
| Q2 FY2022 | Jun 30, 2022 | $158.00K | -100.0% |
| Q1 FY2022 | Mar 31, 2022 | $940.00K | +74.4% |
| Q4 FY2021 | Dec 31, 2021 | $12.90M | +3386.2% |
| Q3 FY2021 | Sep 30, 2021 | $824.00K | +456.8% |
| Q2 FY2021 | Jun 30, 2021 | $900.70M | +2046947.7% |
| Q1 FY2021 | Mar 31, 2021 | $539.00K | +243.3% |
| Q4 FY2020 | Dec 31, 2020 | $370.00K | -99.5% |
| Q3 FY2020 | Sep 30, 2020 | $148.00K | -99.9% |
| Q2 FY2020 | Jun 30, 2020 | $44.00K | -86.2% |
| Q1 FY2020 | Mar 31, 2020 | $157.00K | -52.1% |
| Q4 FY2019 | Dec 31, 2019 | $77.02M | +66870.4% |
| Q3 FY2019 | Sep 30, 2019 | $211.93M | +37542.6% |
| Q2 FY2019 | Jun 30, 2019 | $318.00K | -70.8% |
| Q1 FY2019 | Mar 31, 2019 | $328.00K | -75.8% |
| Q4 FY2018 | Dec 31, 2018 | $115.00K | -99.6% |
| Q3 FY2018 | Sep 30, 2018 | $563.00K | -76.4% |
| Q2 FY2018 | Jun 30, 2018 | $1.09M | -69.6% |
| Q1 FY2018 | Mar 31, 2018 | $1.36M | -49.8% |
| Q4 FY2017 | Dec 31, 2017 | $32.33M | +1279.1% |
| Q3 FY2017 | Sep 30, 2017 | $2.39M | +54.1% |
| Q2 FY2017 | Jun 30, 2017 | $3.58M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.70M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.34M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.55M | – |
See a number that looks wrong?